Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12619000385145
Ethics application status
Approved
Date submitted
26/02/2019
Date registered
12/03/2019
Date last updated
14/10/2022
Date data sharing statement initially provided
12/03/2019
Type of registration
Retrospectively registered

Titles & IDs
Public title
A study of EnGeneIC Dream Vectors (EDV's) packaged with the chemotherapy, E-EDV-D682 given simultaneously as non-targeted EDVs carrying an immune enhancer called EDV-GC, in participants with advanced pancreatic and other cancers whose disease has progressed after one or two treatment regimes, or where other standard therapies are not appropriate.
Scientific title
A Phase I/IIa Study of EGFR-Targeted EDVTMs Carrying the Cytotoxic Drug PNU-159682 (E-EDV-D682) with Concurrent Immunomodulatory Adjuvant Non-Targeted EDVs carrying an immunomodulator (EDV-GC) in (i) Cohort 1, Subjects with Advanced Pancreatic Cancer and (ii) Cohort 2, Subjects with other EGFR Expressing Solid Tumours, who have Failed First or Second-line Therapy or where other Standard Therapies are not Appropriate.
Secondary ID [1] 297385 0
Nil known
Universal Trial Number (UTN)
Trial acronym
The Carolyn Trial / ENG9
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pancreatic Cancer 311538 0
Advanced Cancer (Solid Tumours) 311539 0
Condition category
Condition code
Cancer 310176 310176 0 0
Pancreatic
Cancer 310177 310177 0 0
Any cancer

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is an open-label, Phase I/IIa study of EGFR-targeted EDVs containing the cytotoxic drug PNU-159682 (E-EDV-D682), which is administered intravenously (IV) in combination with immunomodulatory EDV-GC in subjects with advanced pancreatic cancer and other EGFR expressing solid tumours who have failed first or second line therapy, or where other standard therapies are not appropriate.

The Phase I component of the study will enrol 5 patients per cohort (5 patients with advanced pancreatic and 5 patients with other EGFR expressing solid tumours), to evaluate the safety and tolerability of the combination of E-EDV-D682 with adjuvant EDV-GC.
The first treatment cycle for both cohorts (pancreatic patients and participants with other solid tumours), is identical and will comprise of two doses administered 30 minutes apart, the first a combination E-EDV-D682/GC followed by a dose of single agent E-EDV-D682. The 2 doses will be given twice per week for the first 2 weeks (8 doses). After which E-EDV-D682/GC and E-EDV-D682, will be administered weekly for 2 further weeks (4 doses) (12 doses over 4 weeks). Week 5 is treatment free, but tumour burden will be radiologically re-evaluated in accordance with iRECIST to determine treatment response.
Subsequent cycles will follow a weekly dosing schedule, where the same 2 doses, E-EDV-D682/GC followed 30 minutes after completion by E-EDV-D682, will be administered weekly for 4 weeks (8 doses). Following each 4-week treatment period is a treatment free week in which tumour burden is radiologically re-assessed (Week 5).

In order to foster tolerance & minimise potential infusion related reactions, the first dose of combination E-EDV-D682/GC at Cycle 1, will be given at a reduced dose level of 2.5 x 10^9. Subsequent doses (Doses 3, 5, 7, 9 and 11) will then be escalated incrementally until the target dose level, 8 x 10^9, is attained at Cycle 1, Dose 11.

Single agent E-EDV-D682 will commence at a starting dose of 2 x 10^9 at Cycle 1, Dose 2, escalating to a maximum dose level of 7 x 10^9 by Cycle 1, Dose 12. All subsequent cycles of both the combination and E-EDV-D682 alone will be administered at the maximum dose levels attained in Cycle 1.

Participants may continue to receive investigational medicinal product whilst they continue to derive clinical benefit with no prohibitive toxicity, or until the subject becomes intolerant to the study medication, the subject withdraws consent, or at the discretion of the Investigator if it is felt to be in the best interests of the participant to withdraw.

Post-review by the Safety Monitoring Board and authorization by said committee, the Phase IIa component (dose expansion) will open to enrolment. Up to an additional 35 patients/cohort will be recruited to further evaluate the safety and anti-tumour efficacy of the combination of E-EDV-D682 and EDV-GC (E-EDV-D682/GC) as per the schedule outlined.
Intervention code [1] 313640 0
Treatment: Drugs
Comparator / control treatment
No control group.
Control group
Uncontrolled

Outcomes
Primary outcome [1] 319244 0
Assess the safety and tolerability of E-EDV-D682 with EDV-GC in subjects with advanced pancreatic cancer and other EGFR expressing solid tumours who have failed first or second line therapy or where other standard therapies are not appropriate.
Timepoint [1] 319244 0
Safety assessment will involve recording the incidence of Adverse Events (AEs) and clinically significant changes in vital signs and clinical laboratory tests. AE's and vital signs will be assessed pre-dose and then at 1, 2 and 3 hours post-dose infusion for all doses and at the safety withdrawal visit 30-35 days post-final dose.

The very common side effects reported are:
• Chills and shaking (rigors)
• Fever including night sweats
• Abnormalities of liver tests
• Fatigue and lethargy
• Nausea

The common side effects reported are:
• Abnormalities of electrolyte tests
• Headache
• Pain or discomfort at the site of the cancer
• Breathless
• Muscular weakness/aches

A designated Safety Review Committee will assess if any reported adverse event including Serious Adverse Events (SAE's) and Suspected Unexpected Serious Adverse Reactions (SUSAR's) are attributable to the study treatment and fulfill the protocol defined criteria of a Dose Limiting Toxicity (DLT).

Participants will be assessed for DLTs after the first 50 days of treatment. and will include the first 5 patients enrolled in each cohort. In the case of missed doses, the DLT evaluable period will be extended by 7 days for each missed dose so that a DLT evaluable subject is defined as, having received 9 doses and been evaluated for a minimum of 7 days following each dose.
Primary outcome [2] 319245 0
Assess anti-tumour response in subjects with advanced pancreatic cancer and other EGFR expressing solid tumours when administered E-EDV-D682 with EDV-GC.
Timepoint [2] 319245 0
Evidence of anti-tumour activity will be assessed radiologically, and response graded according to iRECIST criteria. The overall response for each subject will be recorded at Week 8 of every cycle of treatment for the duration of treatment. Results for best overall response will be presented for individual participants and for the whole cohort, or relevant subsets, if applicable using frequency counts and percentages.
Primary outcome [3] 319246 0
Assess overall survival (OS) in subjects with advanced pancreatic cancer and other solid tumours when administered E-EDV-D682 with EDV-GC.
Timepoint [3] 319246 0
Survival will be presented as months following administration of Dose 1 for individual subjects, and overall or for relevant subsets if applicable. Survival will continue to be monitored for the duration of the long term follow-up (every 3 months from the safety follow-up visit, for a period of 12 months, and then for the extent of the patients survival). Kaplan Meier curves will be utilised to determine percentage and median survival. There is no control arm for this study. Survival will be compared to historic survival data for individual tumour types.
Secondary outcome [1] 367408 0
Exploratory objective: Assess biomarkers for response such as cellular immune response in patients with advanced pancreatic cancer and other EGFR expressing solid tumours administered E-EDV-D682 with adjuvant EDV-GC (E-EDV-D682/GC).
Timepoint [1] 367408 0
Blood samples will be acquired at scheduled time-points for the duration the patient receives E-EDV-D682/EDV-GC for biomarker analysis.

Eligibility
Key inclusion criteria
1. Eastern Cooperative Oncology Group (ECOG) performance score of 0-1.
2. Life expectancy greater than or equal to 3 months
3. Histologically or cytologically confirmed pancreatic cancer or other solid tumours known to express EGFR including, but not limited to, kidney cancer (renal cell adenocarcinoma), melanoma, bladder cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and head and neck cancer.
4. Measurable disease per iRECIST criteria.
5. Must be able to undergo CT or MRI (+/- PET) evaluation.
6. Available archived primary or metastatic neoplastic tumour tissue available for EGFR expression staining.
7. Adequate haematological function.
8. Adequate renal function
9. Adequate hepatic function
11. Adequate cardiac function with LVEF greater than or equal to 50% at baseline.
12. Serum phosphate levels within normal range (2.1-4.1 mg/dL) at baseline.
13. Cortisol levels within normal range, in accordance with hospital accredited laboratory reference range.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Significant pericardial effusions, pleural effusions or ascites.
2. Concurrent unstable diabetes mellitus or other contraindications for the use of corticosteroids.
3. Subject has experienced a history of coronary artery disease, with or without angina pectoris or myocardial infarction, symptomatic congestive heart failure (New York Heart Association > Class II), uncontrolled hypertension (systolic > 160 mmHg or diastolic > 100 mmHg), or cardiac arrhythmias requiring anti-arrhythmic therapy.
4. Clinically significant electrocardiogram (ECG) changes at enrolment which obscure the ability to assess the PR, QT, and QRS interval; congenital long QT syndrome.
5. Known to be human immunodeficiency virus (HIV), hepatitis B surface antigen or hepatitis C positive; or with a history of chronic active hepatitis or cirrhosis.
6. History of uncontrolled arterial or venous thrombosis. Subjects with a history of arterial or venous thrombosis are eligible if the subject is controlled on low dose molecular weight heparins or low dose aspirin.
7. Active or uncontrolled severe infection.
8. Previous or current primary malignancies at other sites within last 2 years, except:
- In situ carcinoma of the cervix.
- Adequately treated basal cell or squamous cell carcinoma of the skin.
9. Received the following procedures within 28 days prior to receiving their first dose (or has not recovered from the toxic effects of such therapy) including:
- other investigational therapy
- radiotherapy
- any major surgery.
10. Prior other therapies or procedures prior to receiving their first dose:
- Anticoagulation therapy (within 7 days of Study Day 1), except low molecular weight heparins or low dose aspirin.
- QTc interval prolonging medicines should be reviewed and where possible their use should be minimized and alternate medicines that are not QTc interval prolonging considered as substitutes.
11. Known allergy/hypersensitivity to investigational components or excipients (trehalose, monoclonal antibody infusions, interferon therapy, or ciprofloxacin HCl (or other quinolones).
12. Female who is pregnant or breastfeeding.
13. Subject who cannot comply with protocol scheduled study visits or procedures, to the best of the subject and Investigator’s knowledge.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1 / Phase 2
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Due to the small number of subjects to be enrolled findings will be presented in a descriptive manner with no formal statistical comparisons performed. Data will be presented for individual subjects. Where feasible, continuous data will be summarised by the following descriptive statistics: n (number of observations), mean, standard deviation, median, minimum, maximum. Categorical data will be summarised by frequencies and percentages.

Recruitment
Recruitment status
Stopped early
Data analysis
Data collected is being analysed
Reason for early stopping/withdrawal
Participant recruitment difficulties
Date of first participant enrolment
Anticipated
Actual
4/03/2019
Date of last participant enrolment
Anticipated
31/12/2021
Actual
11/03/2022
Date of last data collection
Anticipated
31/10/2022
Actual
Sample size
Target
80
Accrual to date
Final
53
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 13259 0
Peninsula Oncology Centre - Frankston
Recruitment hospital [2] 14510 0
Sydney Adventist Hospital - Wahroonga
Recruitment postcode(s) [1] 25822 0
3199 - Frankston
Recruitment postcode(s) [2] 27522 0
2076 - Wahroonga

Funding & Sponsors
Funding source category [1] 302092 0
Commercial sector/Industry
Name [1] 302092 0
EnGeneIC Pty Limited
Country [1] 302092 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
EnGeneIC Pty Limited
Address
Building 2/25 Sirius Rd.
Lane Cove West
NSW 2066
Country
Australia
Secondary sponsor category [1] 301913 0
None
Name [1] 301913 0
Address [1] 301913 0
Country [1] 301913 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 302771 0
Bellberry Limited Human Research Ethics Committee D (00444)
Ethics committee address [1] 302771 0
Ethics committee country [1] 302771 0
Australia
Date submitted for ethics approval [1] 302771 0
28/11/2018
Approval date [1] 302771 0
04/02/2019
Ethics approval number [1] 302771 0
2018-11-1008

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 44090 0
A/Prof Vinod Ganju
Address 44090 0
Peninsula and Southeast Oncology Suite 7, Level 3 North Building, Frankston Private Hospital, 5 Susono Way, Frankston VIC 3199
Country 44090 0
Australia
Phone 44090 0
+61-3-9781-5244
Fax 44090 0
Email 44090 0
[email protected]
Contact person for public queries
Name 44091 0
Albert Goikhman
Address 44091 0
Peninsula and Southeast Oncology Suite 7, Level 3 North Building, Frankston Private Hospital, 5 Susono Way, Frankston VIC 3199
Country 44091 0
Australia
Phone 44091 0
+61-3-8572-2429
Fax 44091 0
Email 44091 0
[email protected]
Contact person for scientific queries
Name 44092 0
Jennifer MacDiarmid
Address 44092 0
EnGeneIC Pty Limited
Building 2/25 Sirius Rd.
Lane Cove West,
NSW 2066
Country 44092 0
Australia
Phone 44092 0
+61-2-9420-5833
Fax 44092 0
Email 44092 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
For reasons of confidentiality.


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseUpdate on glioma biotechnology.2020https://dx.doi.org/10.1016/j.clineuro.2020.106075
EmbasePhase I/IIa Trial in Advanced Pancreatic Ductal Adenocarcinoma Treated with Cytotoxic Drug-Packaged, EGFR-Targeted Nanocells and Glycolipid-Packaged Nanocells.2024https://dx.doi.org/10.1158/1078-0432.CCR-23-1821
N.B. These documents automatically identified may not have been verified by the study sponsor.